The role of segmental nodes in the pathological staging of non-small cell lung cancer
Tóm tắt
Segmental nodes are not examined routinely in current clinical practice for lung cancer, the role of segmental nodes in pathological staging of non-small cell lung cancer after radical resection was investigated. A total of 113 consecutive non-small cell lung cancer patients who underwent radical resection between June 2009 and December 2011 were retrospectively reviewed. All the operations were performed by the same group of surgeons. N2 nodes, hilar nodes, interlobar nodes and some lobar nodes were collected during surgery. The removed lung lobes were dissected routinely along lobar and segmental bronchi to collect lobar nodes and segmental nodes. The collected lymph nodes were separately labeled for histological examination. The detection rates of hilar nodes, interlobar nodes, lobar nodes and segmental nodes were 61.1%, 85.0%, 75.2% and 80.5%, respectively. The metastasis rates of hilar nodes, interlobar nodes, lobar nodes and segmental nodes were 5.3%, 10.5%, 16.8% and 14.2%, respectively. There were 68 cases of N0 disease, 16 cases of N1 disease and 29 cases of N2 disease. If an analysis of segmental lymph nodes had been omitted, six patients (37.5% of N1 disease) would have been down-staged to N0, and two cases of multiple-zone N1 disease would have been misdiagnosed as single-zone N1 disease, one patient would have been misdiagnosed as N2 disease with skip metastases. Segmental nodes play an important role in the accurate staging of non-small cell lung cancer, and routinely dissecting the segmental bronchi to collect the lymph nodes is feasible and may be necessary.
Tài liệu tham khảo
Rusch VW, Crowley J, Giroux DJ: The IASLC lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2007, 2: 603-612. 10.1097/JTO.0b013e31807ec803.
Arriagada R, Bergman B, Le Dunant A, Chevalier T, Pignon JP, Vansteenkiste J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004, 350: 351-360.
Winton T, Livingston R, Johnson D: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005, 352: 2589-2597. 10.1056/NEJMoa043623.
Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P: The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009, 4: 568-577. 10.1097/JTO.0b013e3181a0d82e.
Detterbeck FC, Boffa DJ, Tanoue LT: The new lung cancer staging system. Chest. 2009, 136: 260-271. 10.1378/chest.08-0978.
Watanabe S, Asamura H: Lymph node dissection for lung cancer: significance, strategy, and technique. J Thorac Oncol. 2009, 4: 652-657. 10.1097/JTO.0b013e31819cce50.
Yang H, Li XD, Lai RC: Complete mediastinal lymph node dissection in video-assisted thoracoscopic lobectomy versus lobectomy by thoracotomy. Thorac Cardiovasc Surg. 2013, 61: 116-123.
Wu Y, Huang ZF, Wang SY, Yang XN, Ou W: A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002, 36: 1-6. 10.1016/S0169-5002(01)00445-7.
Darling GE, Allen MS, Decker PA: Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American college of surgery oncology group Z0030 trial. J Thorac Cardiovasc Surg. 2011, 141: 662-670. 10.1016/j.jtcvs.2010.11.008.
Izbicki JR, Passlick B, Pantel K: Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg. 1998, 227: 138-144. 10.1097/00000658-199801000-00020.
Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR: Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg. 2002, 21: 520-526. 10.1016/S1010-7940(02)00004-0.
Sugi K, Nawata K, Fujita N: Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg. 1998, 22: 290-294. 10.1007/s002689900384. discussion 294–5
Darling GE, Allen MS, Decker PA: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American college of surgeons oncology group Z0030 trial. Chest. 2011, 139: 1124-1129. 10.1378/chest.10-0859.
Liu Z, Bi Y, Tian H: Basic and Clinical of Lymph. 2003, Beijing: Science Press, 1
Yamanaka A, Hirai T, Fujimoto T, Ohtake Y, Konishi F: Analyses of segmental lymph node metastases and intrapulmonary metastases of small lung cancer. Ann Thorac Surg. 2000, 70: 1624-1628. 10.1016/S0003-4975(00)01923-8.
Matsuoka K, Sumitomo S, Misaki N: Prognostic factors in patients with pathologic T1-2N1M0 disease in non-small cell carcinoma of the lung. J Thorac Oncol. 2007, 2: 1098-1102. 10.1097/JTO.0b013e31815ba227.
Wu N, Yan S, Zheng QF: Role of pulmonary segmental and sub-segmental lymph nodes in pathological staging of lung cancer. Zhonghua Yi Xue Za Zhi. 2010, 90: 1873-1876.
Osaki T, Nagashima A, Yoshimatsu T, Tashima Y, Yasumoto K: Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer. 2004, 43: 151-157. 10.1016/j.lungcan.2003.08.020.
Maeshima AM, Tsuta K, Asamura H: Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status[J]. Cancer. 2012, 118 (18): 4512-4518. 10.1002/cncr.27424.
Casali C, Stefani A, Morandi U: N1 non-small-cell lung cancer. A 20-year surgical experience. Asian Cardiovasc Thorac Ann. 2011, 19: 217-224. 10.1177/0218492311407904.
Sayar A, Turna A, Kilicgun A, Solak O, Urer N, Gurses A: Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung. Eur J Cardiothorac Surg. 2004, 25: 434-438. 10.1016/j.ejcts.2003.12.005.
Cerfolio RJ, Bryant AS: Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer. Ann Thorac Surg. 2007, 84: 182-188. 10.1016/j.athoracsur.2007.03.030. discussion 189–90
Ueda K, Kaneda Y, Sakano H: Independent predictive value of the overall number of metastatic N1 and N2 stations in lung cancer. Jpn J Thorac Cardiovasc Surg. 2003, 51: 297-301. 10.1007/BF02719381.
Yoshino I, Yokoyama H, Yano T: Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer. Ann Thorac Surg. 1996, 62: 1021-1025. 10.1016/0003-4975(96)00470-5.
Wang S, Wu Y, Ou W: Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2001, 23: 259-261.
Prenzel KL, Monig SP, Sinning JM: Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancer. J Surg Oncol. 2003, 82: 256-260. 10.1002/jso.10219.
Misthos P, Sepsas E, Athanassiadi K, Kakaris S, Skottis I: Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg. 2004, 25: 502-508. 10.1016/j.ejcts.2004.01.025.